Use of gadolinium for MRI diagnostic or surveillance studies in patients with MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published July 8, 2019.
Article Versions
- Previous version (July 8, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Lukas Haider,
- Robert T. Naismith and
- Alex Rovira
- Lukas Haider,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
ESNR (European Society of Neuro-radiology) Research Fellowship ECTRIMS-MAGNIMS Research Fellowship
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert T. Naismith and
1) Alkermes
NONE
1) Acorda Therapeutics, speaker honoraria and travel (commercial) 2) Alkermes, consulting and travel (commercial) 3) Celgene, consulting and travel (commercial) 4) Biogen IDEC, speaker honoraria and travel (commercial) 5) Genentech, speaker honoraria and travel (commercial) 6) Genzyme Corporation, speaker honoraria and travel (commercial) 7) EMD Serono, consulting honoraria and travel (commercial) 8) Novartis, consulting honoraria and travel (commercial) 9) TG Therapeutics, consulting honoraria (commercial) 10 Alexion, consulting honoraria (commercial)
Journal Watch 2010-present, Associate Editor
NONE
NONE
NONE
NONE
1) Acorda Therapeutics (commercial) 2) EMD Serono (commercial) 3) Genzyme Corporation (commercial) 4) Genentech (commercial) 5) Novartis (commercial)
NONE
NONE
NONE
NONE
NONE
National MS Society National Institutes of Health
NONE
NONE
NONE
NONE
NONE
NONE
- Alex Rovira
(1) Novartis, (2) Biogen, (3) Genzyme, (4) OLEA Medical, (5) Icometrix, (6) Synthetic MRI, (7) Bayer
NONE
(1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA Medical, (8) Roche
Editorial boards of:(1) Am J Neuroradiol. Editorial board member, 2008 at present;(2) Neuroradiology. Editorial board member, 2006 at present;(3) European Radiology, 2016 at present
NONE
NONE
NONE
NONE
(1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA Medical, (8) Stendhal, (9) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the NMR Research Unit (L.H.), Queens Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Science, University College London, UK; Department of Biomedical Imaging and Image Guided Therapy (L.H.), Medical University of Vienna, Austria; Washington University School of Medicine (R.T.N.), Saint Louis, MO; and Section of Neuroradiology, Department of Radiology (A.R.), University Hospital Vall d'Hebron, Barcelona, Spain.
- Correspondence
Dr. Haider l.haider{at}ucl.ac.uk
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.